Results 111 to 120 of about 8,708 (251)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data

Frontiers in Pediatrics, 2020
Ceftolozane-tazobactam is a novel fifth-generation cephalosporin/β-lactamase inhibitor combination recently approved for treatment of both complicated intra-abdominal and urinary tract infections in adults.
Silvia Garazzino, Elena Altieri, Erika Silvestro, Giulia Pruccoli, Carlo Scolfaro, Elisabetta Bignamini   +5 more
doaj   +1 more source

Advances in antibiotic therapy in the critically ill [PDF]

, 2016
Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains ...
Antonelli, Massimo, Bassetti, Matteo, Calandra, Thierry, Chastre, Jean, De Backer, Daniel, François, Bruno, Karam, George, Rello, Jordi, Roberts, Jason A., Taccone, Fabio S., Torres, Antoni, Universitat Autonoma de Barcelona, Vincent, Jean-Louis, Welte, Tobias   +13 more
core   +2 more sources

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy
Background Ceftolozane/tazobactam and ceftazidime/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared outcomes between non-COVID-19 hospitalized patients with MDR-PSA PNA who received ...
T. Lodise, E. Obi, Alexandre H. Watanabe, Emre Yucel, Jae S. Min, Brian H Nathanson   +5 more
semanticscholar   +1 more source

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways

Case Reports in Infectious Diseases, 2018
Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed by ...
Erik Skoglund, Henrietta Abodakpi, Rafael Rios, Lorena Diaz, Elsa De La Cadena, An Q. Dinh, Javier Ardila, William R. Miller, Jose M. Munita, Cesar A. Arias, Vincent H. Tam, Truc T. Tran   +11 more
doaj   +1 more source

Интраабдоминальная инфекция в свете последних международных рекомендаций и ее роль в развитии септической энцефалопатии [PDF]

, 2018
Цель данных рекомендаций: представить международную позицию, основанную на доказательствах, по вопросам тактики ведения интраабдоминальных инфекций и влияние интраабдоминальных инфекций на развитие септической энцефалопатии.
Лисничая, В.Н., Мальцева, Л.А., Мосенцев, Н.Ф.   +2 more
core  

Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age [PDF]

, 2019
AIMS Beta-lactam dose optimization in critical care is a current priority. We aimed to review the pharmacokinetics (PK) of three commonly used beta-lactams (amoxicillin ± clavulanate, piperacillin-tazobactam and meropenem) to compare PK parameters ...
Baker, Emma H, Barker, Charlotte, Kipper, Karin, Lonsdale, Dagan O, Philips, Barbara, Rhodes, Andrew, Sharland, Mike, Standing, Joseph F   +7 more
core   +2 more sources

Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study

Frontiers in Microbiology
Introduction Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) is a growing concern due to its increasing incidence, limited therapeutic options, limited data on the optimal treatment, and high mortality rates.
Diogo Mendes Pedro, Sérgio Eduardo Paulo, C. Santos, Ana Bruschy Fonseca, J. Melo Cristino, Álvaro Ayres Pereira, C. Caneiras   +6 more
semanticscholar   +1 more source

Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department [PDF]

, 2018
Background: The aim of this study was to identify clinical risk factors for antimicrobial resistances and multidrug resistance (MDR) in urinary tract infections (UTI) in an emergency department in order to improve empirical therapy. Methods: UTI cases
Bischoff, Sebastian, Ebert, Matthias, Gerigk, Marlis, Vogelmann, Roger, Walter, Thomas   +4 more
core   +1 more source

Pseudomonas aeruginosa antibiootikumiresistentsus 21. sajandil [PDF]

, 2015
Pseudomonas aeruginosa on patogeen, mis tõmbab tähelepanu eelkõige oma võimega muutuda antibiootikumide suhtes resistentseks. See protsess on aastakümneid olnud kiirem meie võimest vastata uute antibiootikumidega.
Lutsar, Irja, Türk, Silver
core   +2 more sources

Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy

Antibiotics
The optimal doses of ceftazidime–avibactam (CZA) and ceftolozane–tazobactam (C/T) for treating multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) in patients utilizing renal replacement therapy (RRT) are not well established.
W. E. El Nekidy, Mooza Al Ali, E. Abidi, R. El Lababidi, Diaa Alrahmany, Islam M. Ghazi, M. Mooty, Fadi A. Hijazi, Muriel Ghosn, J. Mallat   +9 more
semanticscholar   +1 more source